PT125 - PURE-02: An open label, multicenter, single-arm, phase 2 study of neoadjuvant pembrolizumab (Pembro), preceding radical nephroureterectomy (RNU), for patients with localized high-risk urothelial carcinoma of the upper urinary tract (UTUC)
References (0)
Cited by (0)
Copyright © 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.